Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00122070|
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : June 10, 2008
The objective of this study is to quantitatively examine the efficacy of Seroquel (active ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD). A secondary objective is to characterize the safety and tolerability of utilizing quetiapine in patients with Borderline Personality Disorder.
Investigator initiated, 6-week, non-placebo controlled, non-randomized, open-label, single drug, single-center, medication trial.
Volunteers (n = 15) diagnosed with Borderline Personality Disorder using the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II).
Subjects with Borderline Personality Disorder are washed out of all other medications. The subjects are then given the study drug at a dose within the drug's known therapeutic range.
|Condition or disease||Intervention/treatment||Phase|
|Borderline Personality Disorder||Drug: Quetiapine Fumarate||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||September 2007|
|Actual Study Completion Date :||May 2008|
Quetiapine at dosage of 50 to 150 mg
Drug: Quetiapine Fumarate
Dosage can vary from 50 to 150 mg at PI's discretion
Other Name: Seroquel
- Symptom Checklist 90 scale (SCL-90-R) [ Time Frame: 8 weeks ]
- Safety and tolerability will be measured at Baseline and weekly using the following scales: Simpson-Angus Extrapyramidal Side Effect Scale (SAS), Barnes Akathisia Scale (BAS), and Abnormal Involuntary Movement Scale (AIMS). [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00122070
|United States, New Jersey|
|University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine - Department of Psychiatry|
|Cherry Hill, New Jersey, United States, 08002-2000|
|Principal Investigator:||David J Rissmiller, DO||University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine|